In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

The AOP, along with headline sponsor Bausch + Lomb, are pleased to deliver the Hospital and ... which have been used to create five content streams: Anterior eye stream Contact lenses stream Glaucoma ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Financial analyst predicts Bausch & Lomb (BLCO) could be worth $28/share in a potential takeover, with private equity ...

Bausch + Lomb BLCO. The industry declined 0.6% during this timeframe. The sale, intended to separate both companies, is stuck for quite some time now. Hence, reports of BHC moving forward have ...

Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Bausch & Lomb (NYSE:BLCO) rose 1.8% in premarket trading after a report about private equity interest in a takeover of the ...